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Sarcopenia is the age-related progressive loss of skeletal muscle mass and strength
finally leading to poor physical performance. Impaired myogenesis contributes to
the pathogenesis of sarcopenia, while mitochondrial dysfunctions are thought to
play a primary role in skeletal muscle loss during aging. Here we studied the link
between myogenesis and metabolism. In particular, we analyzed the effect of the
metabolic modulator trimetazidine (TMZ) on myogenesis in aging. We show that
reprogramming the metabolism by TMZ treatment for 12 consecutive days stimulates
myogenic gene expression in skeletal muscle of 22-month-old mice. Our data also
reveal that TMZ increases the levels of mitochondrial proteins and stimulates the
oxidative metabolism in aged muscles, this finding being in line with our previous
observations in cachectic mice. Moreover, we show that, besides TMZ also other
types of metabolic modulators (i.e., 5-Aminoimidazole-4-Carboxamide Ribofuranoside-
AICAR) can stimulate differentiation of skeletal muscle progenitors in vitro. Overall,
our results reveal that reprogramming the metabolism stimulates myogenesis while
triggering mitochondrial proteins synthesis in vivo during aging. Together with the
previously reported ability of TMZ to increase muscle strength in aged mice, these new
data suggest an interesting non-invasive therapeutic strategy which could contribute
to improving muscle quality and neuromuscular communication in the elderly, and
counteracting sarcopenia.
Keywords: metabolic reprogramming, myogenesis, trimetazidine, mitochondria, aging, neuromuscular activity,
sarcopenia, metabolism
INTRODUCTION
Loss of muscle mass and strength (often referred to as sarcopenia) are among the most relevant
changes occurring in aging (Janssen et al., 2004; Lopez-Otin et al., 2013). Impairment of myogenesis
contributes to sarcopenia; in fact, muscles of aged individuals display a low reservoir of resident
skeletal muscle stem cells – satellite cells (SCs) – which are also characterized by impaired myogenic
potential (Conboy et al., 2003; Carlson et al., 2009; Snijders et al., 2009; Shefer et al., 2010; Blau et al.,
2015; Sousa-Victor and Munoz-Canoves, 2016). Moreover, mitochondrial dysfunctions play a key
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role in sarcopenia (Peterson et al., 2012; Hill and Van Remmen,
2014) and energy management is crucial also for SC fate; in
particular, favoring the oxidative metabolism seems to enhance
myogenic capabilities (Cerletti et al., 2012; Ryall, 2013; Ryall
et al., 2015a). Although the precise mechanisms have to be
elucidated, during the transition from quiescence to activation,
proliferation, and differentiation, SCs have to meet specific
bioenergetic demands and undergo metabolic changes which
regulate chromatin accessibility and transcription (Cervelli et al.,
2009; Ryall, 2013; Ryall et al., 2015b; Ryall and Lynch, 2018).
Moreover, slow-oxidative myofibers are associated to more SCs
and capillaries compared to fast-glycolytic myofibers (Christov
et al., 2007; Yin et al., 2013), and high local oxygen concentration
stimulates SC differentiation (Christov et al., 2007).
Based on these premises, we hypothesize that an optimization
of energy production through metabolic reprogramming might
be an interesting strategy for both counteracting mitochondrial
dysfunctions and supporting SC function, so improving
myogenesis in aging. In support of this hypothesis, we have
previously shown that the metabolic modulator trimetazidine
(TMZ) – shifting the energy metabolism from fatty acid
to glucose oxidation, thus enhancing metabolic efficiency
(Jaswal et al., 2011; Zhao et al., 2016) – increases muscle
strength in aged mice and stimulates myoblast differentiation
in vitro (Ferraro et al., 2016; Gatta et al., 2017). The main
aim of this study was to investigate the effect of TMZ on
myogenesis in aging. Moreover, other metabolic modulators
were tested for their ability to improve the myogenic potential
of SC in vitro.
MATERIALS AND METHODS
Animals
Mice were cared for in compliance with the Italian Ministry of
Health Guidelines (n◦ 86609 EEC, permit number 106/2007-B)
and the Policy on Human Care and Use of Laboratory Animals
(NIH 1996) (Ferraro et al., 2016). 22-month-old C57BL6/J
male mice were divided into two groups (n = 6 each); one
group received 5 mg/kg TMZ (Alfa Aesar Thermofisher) by
intraperitoneal injection twice a day for 12 days, the control
group received PBS injections. Balb-c mice were inoculated
dorsally with C26 colon-carcinoma cells and treated or not (n = 7
per group) with 5 mg/kg TMZ once a day for 12 days (Molinari
et al., 2017). Healthy Balb-c mice administered or not TMZ (n = 6
per group) were used as controls. 12 days after TMZ-treatment
the animals were sacrificed and gastrocnemius, tibialis anterior
and hearts were excised and stored at−80◦C.
Western Blotting
Gastrocnemius and hearts lysates (obtained by centrifugation
of homogenates) were separated by SDS-PAGE, transferred to
nitrocellulose membranes and probed using antibodies against
MyoD, Myogenin (M3512, M3559-Dako), Desmin, Collagen
type-III, α-SMA (D1033, C7805, A5228-Sigma-Aldrich), PGC1α,
β-ATPase (AB3242, MAB3494-Millipore), TFAM, Tom20, CSQ2,
fsTn-I, VEGF, VE-Cadherin, PECAM, SDHA and PPARγ (sc-
23588, sc-11415, sc-390999, sc-377382, sc-7269, sc-9989, sc-
46694, sc-377302, sc-7273-Santa Cruz Biotechnology), CoxIV
(Ab14744-Abcam) and the appropriate secondary antibodies.
α-tubulin or actin (T5168, A3853-Sigma-Aldrich) were used
for normalization. Quantification was performed as previously
described (Ferraro et al., 2016).
Quantitative RT-PCR
RNA isolation was performed as previously described (Ferraro
et al., 2016). cDNA was synthesized with the GoScript Reverse
Transcription System (Promega). qRT-PCR was performed with
the SYBR-green master mix (Promega) by using an Applied
Biosystem Step One PCR system. Data were normalized to 18S
and analyzed using the comparative CT (2-11CT) method.
C2C12 Cell Culture, Satellite Cells
Isolation, and Treatments
C2C12 skeletal myoblasts were cultured in growth medium (GM;
DMEM supplemented with 20% FBS). Before confluency the GM
was replaced with differentiation medium (DM; supplemented
with 2% horse serum) with or without AICAR (Enzo Life
Sciences). As for SCs isolation, the manufacturer (Miltenyi
Biotec)’s instructions were followed (Gatta et al., 2017). The
purified cells were then resuspended in DMEM supplemented
with 10% FBS, 20% HS, and 3% CEE, and seeded in collagen
precoated dishes.
Fluorescence Microscopy
Cells or Tibalis anterior cross-sections were immunostained
as previously described (De Luca et al., 2013) with anti-
MyHC (MF20-DSHB), Myogenin (sc-576), Pax7 (DSHB), and
PECAM antibodies overnight at 4◦C. Fluorofore-conjugated
secondary antibodies were applied 1 h at RT and nuclei were
counterstained with Hoechst.
Metabolic Analysis
Metabolic analysis was performed using the Seahorse-XF24 Flux
Analyzer (Agilent Technologies). C2C12 cells were seeded onto
XF24 plates. The following day 10 µM TMZ was added. On
the day of the analysis, the medium was replaced with XF-Base
medium ± 10 µM TMZ and plates were incubated for 30 min at
37◦C in a CO2-free incubator. Oxygen Consumption Rate (OCR)
was measured for the basal state, and followed by the sequential
injection of oligomycin, FCCP and a AntimycinA+Rotenone
(Berghella and Ferraro, 2012; Divakaruni et al., 2014).
Sirius Red Staining
Tibialis anterior cryo-sections fixed with Bouin’s solution (Sigma-
Aldrich) for 1 h were stained with Picro-Sirius Red dye (Sigma-
Aldrich) for 1 h.
Statistical Analysis
Data are presented as mean± standard error (SEM). Distribution
of data was checked by Kolmogorov–Smirnov test and Shapiro–
Wilk normality test. For normally distributed data, statistical
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FIGURE 1 | Trimetazidine stimulates myogenic and mitochondrial gene expression. (A) Gastrocnemius extracts from untreated aged mice (Ctrl) and TMZ-treated
aged mice (TMZ) were assayed for MyoD Myogenin and Desmin protein levels, (B) for the mRNA levels of MyoD, Myogenin, Desmin, MyHC, PGC1α, GLUT4, and
CPT1 which were evaluated by qRT-PCR, and (C) for β-ATPase, TFAM, Tom20, PGC1α, and α-SMA protein levels. Protein levels of representative four out of six
(Continued)
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FIGURE 1 | Continued
untreated mice and five out of six TMZ-treated mice are shown. (D) Heart extracts from untreated aged mice (Ctrl) and TMZ-treated aged mice (TMZ) were assayed
for PGC1α, β-ATPase, TFAM, and Tom20 protein levels and (E) for CSQ2 and fsTn-I protein levels. Protein levels of representative four out of six untreated mice and
4/5 out of six TMZ-treated mice are shown. (F) Heart RNA extracted from untreated aged mice (Ctrl) and TMZ-treated aged mice (TMZ) was assayed for the mRNA
levels of α-MyHC and β/slow-MyHC which were evaluated by qRT-PCR. In all WB density of immunoreactive bands was calculated using the ImageQuant TL
software from GE Healthcare Life normalized for α-tubulin or actin used as loading control. Each value indicates the mean ± SEM (reported as percentage of Ctrl) of
the densitometric analysis on three independent immunoblots. In all qRT-PCRs, data were normalized to 18S ribosomal RNA used as internal control. Data display
the percentage of mRNAs relative to control. Data shown are the mean ± SEM from three experiments each performed in duplicate. For all experiments ∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001 by Student′s t-test or Mann–Whitney U test as appropriate. Primers used: 18S: Fw-5′-CCCTGCCCTTTGTACACACC-3′ Rv-5′-CGA
TCCGAGGGCCTCACTA-3′; MyoD Fw-5′-CCCCGGCGGCAGAATGGCTACG-3′ Rv-5′-GGTCTGGGTTCCCTGTTCTGTG-3′; Myogenin: Fw-5′-GGGCCCCTGGAA
GAAAAG-3′ Rv-5′-AGGAGGCGCTGTGGGAGT-3′; Desmin: Fw-5′-GAGGTTGTCAGCGAGGCTAC-3′ Rv-5′-GAAAAGTGGCTGGGTGTGAT-3′; MyHC Fw-5′-CAAG
TCATCGGTGTTTGTGG-3′ Rv-5′-TGTCGTACTTGGGAGGGTTC-3′; CTP1: Fw-5′-CCCATGTGCTCCTACCAGAT-3 Rv-5-CCTTGAAGAAGCGACCTTTG-3; PGC1α:
Fw-5′-GTCAACAGCAAAAGCCACAA-3 Rv-5′-TCTGGGGTCAGAGGAAGAGA-3′; GLUT-4: Fw-5′-GGCATGGGTTTCCAGTATGT-3′ Rv-5′-GCCCCTCAGTCATTC
TCATG-3′; α-MyHC: Fw-5′-AACAACCCATACGACTACGCC-3′ Rv-5′-CAGCATCTTCTGTGCCATCA-3′; β/slow-MyHC Fw-5′-TGCAGCAGTTCTTCAACCAC-3′
Rv-5′-TCGAGGCTTCTGGAAGTTGT-3′; VEGF: Fw-5′-CTGTGCAGGCTGCTGTAACG-3′ Rv-5′-GTTCCCGAAACCCTGAGGAG-3′; MyHC: Fw-5′-TCGTCTCGCTT
TGGCAA-3′ Rv-5′-TGGTCGTAATCAGCAGCA-3′.
differences between two groups were verified by Student’s
t-test (two-tailed). For non-parametric variables, groups were
compared by Mann–Whitney U test. For the comparison
between more than two groups Kruskal–Wallis test was
performed. P < 0.05 was considered significant. The statistical
analyses were performed using SPSS 25.0 (SPSS Inc., 2019).
RESULTS
Metabolic Reprogramming Stimulates
Myogenic and Oxidative Gene
Expression in the Skeletal Muscle of
Aged Mice
Skeletal muscle of 22-month-old mice treated with the metabolic
modulator TMZ for 12 days were assayed for the expression of
myogenic markers by qRT-PCR and WB analysis which revealed
MyoD, Myogenin, Desmin, and eMHC up-regulation following
TMZ treatment (Figures 1A,B). Moreover, TMZ stimulated the
expression of mitochondrial and oxidative metabolism markers
such as mitochondrial transcription factor A (TFAM) and
mitochondrial protein Tom20 (Figure 1C). This is in line
with the observed TMZ-mediated induction of peroxisome
proliferator-activated receptor gamma (PPARγ)-coactivator-1-
alpha (PGC1α), a master regulator of mitochondrial biogenesis
also involved in myogenesis (Figures 1B,C; Haralampieva et al.,
2017, 2018). Moreover, the up-regulation of mitochondrial
ATP-synthase β-subunit (β-ATPase), succinate-dehydrogenase
complex subunit-A (SDHA), cytochrome-c-oxidase (CoxIV), and
PPARγ (Figure 1C) were indicative of a reprogramming toward
a more oxidative metabolism. Increase of Glut4 transcript levels
is also triggered by TMZ (Figure 1B), consistently with our
previous data showing that this drug enhances glucose uptake
(Ferraro et al., 2013, 2016).
Overall, these data confirm that, in sarcopenic skeletal
muscles, TMZ is able to modulate the levels of markers of
myogenesis and mitochondrial homeostasis.
Interestingly, we also observed a marked TMZ-dependent
increase of α-smooth muscle actin (α-SMA) in aged muscles
(Figure 1C), as well as in muscles of tumor-bearing cachectic
mice (Supplementary Figure S1). α-SMA over-expression could
reflect enhanced capillarization, which would be consistent
with TMZ-induced up-regulation of vascular endothelial growth
factor (VEGF), as reported in Supplementary Figure S2A. VEGF
protein levels also tended to increase, although not significantly
(Supplementary Figure S2B). However, VEGF induction was
not associated with increased capillarization, as evaluated by
PECAM staining and by vascular endothelial (VE)-cadherin WB
detection (Supplementary Figure S2C and data not shown).
α-SMA is also a marker of myofibroblasts which contribute to
fibrosis (Li and Huard, 2002); however, the positivity to Sirius Red
staining was not different between TMZ-treated and untreated
muscles (Supplementary Figure S2D). This result, together with
the observation that Collagen III levels were not influenced by
TMZ (Supplementary Figure S2A) rule out an effect of the drug
on fibrosis
Since TMZ has been extensively studied for its effect on
myocardium (Jaswal et al., 2011; Zhao et al., 2016), we also
evaluated TMZ’s effect on cardiac mitochondrial proteins, and
we found increased expression of PGC1α and β-ATPase, whereas
no significant changes were observed on TFAM and Tom20
(Figure 1D). The stronger TMZ’s effect on skeletal muscle
mitochondria compared to cardiac ones might be explained
by the higher plasticity of the former tissue compared to the
latter, resulting in a fast response to environmental stimuli.
Interestingly, we also found that, in the heart, TMZ stimulated the
expression of the sarcoplasmic reticulum Ca2+-binding protein
calsequestrin-2 (CSQ2) and of the slow-twitch myosin heavy
chain β-isoform (β/slow-MyHC) while reducing the expression of
the fast isoform of troponin-I (fsTn-I) and having no effect on the
fast α-MyHC (Figures 1E,F). Since we have recently shown that
TMZ stimulates a fast-to-slow myofiber switch (Molinari et al.,
2017), it is worth mentioning that the CSQ2 isoform, similarly to
β/slow-MyHC are typically expressed in cardiomyocytes as well
as in slow-twitch skeletal muscles.
Similarly to TMZ, Other Metabolic
Modulators Can Potentiate Myogenesis
To evaluate if myogenesis can be stimulated by other metabolic
modulators, we tested the effect of an activation of AMPK
by 5-Aminoimidazole-4-Carboxamide Ribofuranoside (AICAR).
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FIGURE 2 | Similarly to TMZ, also AICAR stimulates myogenic differentiation. (A) The mRNA levels of Myogenin and PGC1a were evaluated by quantitative real time
PCR in C2C12 myoblasts differentiating for 4 and 18 h with or without 0.5 mM AICAR. The mRNA expression values were normalized to those of 18S ribosomal
RNA, used as internal control, and are displayed as folds relative to a plate reference control sample (0 h in differentiation medium, not shown). Data shown are the
mean ± SEM from four experiments each performed in triplicate. ∗∗p ≤ 0.01 by two-tailed Student’s t-test. (B) The mRNA levels of MyoD, Myogenin, and MyHC
were evaluated by quantitative real time PCR in primary satellite cells cultured for 24 h and then treated with 0.5 mM AICAR for further 24 h (total 48 h in culture), or
(Continued)
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FIGURE 2 | Continued
cultured for 48 h and then treated with 0.5 mM AICAR for further 4 or 24 h (total 52 or 72 h in culture, respectively). The mRNA expression values were normalized to
18S RNA used as internal control, and are displayed as folds relative to a plate reference control sample (48 h in culture without AICAR treatment). Data shown are
the mean ± SEM from three experiments, each performed in triplicate. ∗p < 0.05, ∗∗p ≤ 0.01, and ∗∗∗p ≤ 0.005 by two-tailed Student’s t-test. (C) Satellite cells
were cultured for 6 h and then treated with or without 0.5 mM AICAR for 10 h before fixation and co-immunostaining for myogenin (red) and Pax7 (green). The graph
represents the quantification of myogenin+/Pax7-, myogenin+/Pax7+, or myogenin-/Pax7+ cells. Data are the means ± SEM from three experiments and are
expressed as the percentage in each category of the total positive cells. For each experiment, at least 10 microscopy fields were analyzed for a total of at least 1000
cells counted for each condition. (D,E) Satellite cells were cultured in 35 mm collagen-coated dishes for 12 h and then treated with or without 0.5 mM AICAR for 22,
40, or 70 h before fixing and immunostaining for MyHC (green). Counterstaining with Hoechst was used to visualize all nuclei (blue). The graph represents the
quantification of fusion index at 34 and 52 h. Data are from three independent experiments. Values are expressed as the mean ratio ± SEM of nuclei present in
myotubes, containing at least three nuclei, to the total number of nuclei. Asterisks denote significance (∗∗p < 0.01, ∗∗∗p < 0.001). Scale bar: 50 µm.
Indeed, metabolic reprogramming driven by AICAR could
influence skeletal myoblast differentiation in vitro. Specifically,
while high concentrations of AICAR (2 mM) resulted toxic
for C2C12 myoblasts (Supplementary Figure S3), 0.5 mM
AICAR induced the differentiation marker myogenin and
PGC1α (Figure 2A). Corroborating these findings, we found
that differentiation of SC cultures was enhanced by AICAR,
as demonstrated by increased MyoD, myogenin and MyHC
mRNA levels (Figure 2B). Furthermore, co-immunostaining
for myogenin and the SC marker Pax7 revealed a precocious
onset of differentiation triggered by AICAR, as indicated by
an increase in the fraction of cells expressing myogenin or co-
expressing myogenin and Pax7, with a reciprocal decrease of only
Pax7-positive cells (Figure 2C). At later stages of myogenesis,
immunostaining for MyHC revealed, for AICAR-treated cells,
a fusion index higher compared to controls and much larger
myotubes (Figures 2D,E).
Based on the above data and on our previous results
showing stimulation of in vitro myoblast differentiation by TMZ
(Gatta et al., 2017), and taking into account that myogenic
differentiation is associated with an increased mitochondrial
mass (Moyes et al., 1997; Barbieri et al., 2011), we assessed the rate
of respiration of C2C12 myoblasts undergoing differentiation
with and without TMZ. Unexpectedly, the OCR during myoblast
differentiation was similar in both conditions (Supplementary
Figures S4A,B). A trend toward increased oxygen consumption
was only observed when myoblasts were cultured in GM without
pyruvate and were acutely treated with TMZ for 20 min
(Supplementary Figures S4C,D).
DISCUSSION
The present study demonstrates the ability of TMZ to potentiate
myogenesis in aged muscle. This correlates and potentially
explains the high number of centro-nucleated myofibers and
a shift toward smaller cross-sectional areas we have previously
observed after TMZ treatment in aged mice, (Ferraro et al., 2016).
Moreover, our findings are also in line with the ability of TMZ
to enhance myoblast differentiation in vitro and in cachectic
tumor-bearing mice (Gatta et al., 2017).
Our results also reveal that TMZ up-regulates mitochondrial
proteins and stimulates the oxidative metabolism in aged mice,
similarly to previous observations in cachectic mice (Moyes
et al., 1997; Barbieri et al., 2011; Molinari et al., 2017).
Carnitine palmitoyltransferase-I (CPT1) up-regulation suggests
a metabolic compensative response to TMZ-induced fatty acid
β-oxidation reduction (Figure 1B).
Particularly interesting, although subject to various
interpretations, is the marked α-SMA induction triggered
by TMZ (Figure 1C and Supplementary Figure S1). α-SMA
is a marker of perycites, cells with supportive function strictly
associated to the microvessel endothelium and abundant in
angiogenic sprouts (Armulik et al., 2005). The increase of α-SMA
expression could suggest enhanced capillarization triggered by
TMZ, which would be consistent with VEGF up-regulation,
although VE-cadherin and PECAM levels do not change upon
TMZ treatment. We hypothesize that 12 days of TMZ treatment
might be enough to induce VEGF but not its downstream
effects on capillarization. Moreover, pericytes significantly
contribute to skeletal myogenesis and α-SMA is also expressed
in myoblasts (Dellavalle et al., 2007, 2011; Cappellari and
Cossu, 2013), this being in line with the observed stimulation
of myogenesis by TMZ. Additionally, during adult skeletal
muscle regeneration, some regenerating fibers express α-SMA
(Chaponnier and Gabbiani, 2016).
Here we also show that, besides TMZ, also the metabolic
reprogramming agent AICAR can promote myoblast
differentiation. Similarly, ranolozine has been proposed as
having the same effect (Terruzzi et al., 2017). Notably, in contrast
to our data, AICAR has previously been shown to inhibit C2C12
differentiation (Williamson et al., 2009) These contradictory
results might be due to the different AICAR concentrations used,
indeed, here we demonstrated that high AICAR concentrations
are toxic for myoblasts.
Finally, we report a trend to oxygen consumption increase in
TMZ-treated myoblasts cultured in GM and without pyruvate,
possibly because the presence of high pyruvate concentration
in the medium might mask the metabolic shift from fatty
acid to glucose oxidation triggered by TMZ which increases
pyruvate. Similarly, the DM would hide a mild stimulatory
effect on differentiation.
Overall, these data confirm the occurrence of a clear effect of
TMZ, and potentially of other modulators of the metabolism,
both on myogenesis and on mitochondria homeostasis. Given
that TMZ also increases muscle strength in aged animals
(Ferraro et al., 2016), this and other metabolic modulators appear
promising as therapeutic agents, thanks to their potential to
counteract sarcopenia and improve neuromuscular activity, thus
increasing elderly people’s self-sufficiency.
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